Evidence map›Paper›PMID 39871242›Full record

ArticleBMC complementary medicine and therapies2025

Essential oils from Amorpha fruticosa against hepatocellular carcinoma based on network pharmacology.

Yixian Liu, Xiaojun Zhang, Jiacong Hao, Ying Zhao, Min Zou, Huiping Chen, Jintao Zhang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC complementary medicine and therapies, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Yixian LiuHenan Institute of Medical and Pharmaceutical Sciences, Zhengzhou University, Zhengzhou, China.
Xiaojun ZhangHenan Institute of Medical and Pharmaceutical Sciences, Zhengzhou University, Zhengzhou, China.
Jiacong HaoHenan Institute of Medical and Pharmaceutical Sciences, Zhengzhou University, Zhengzhou, China.
Ying ZhaoHenan Institute of Medical and Pharmaceutical Sciences, Zhengzhou University, Zhengzhou, China.
Min ZouHenan Institute of Medical and Pharmaceutical Sciences, Zhengzhou University, Zhengzhou, China.
Huiping ChenHenan Institute of Medical and Pharmaceutical Sciences, Zhengzhou University, Zhengzhou, China. baihe7879@126.com.
Jintao ZhangHenan Institute of Medical and Pharmaceutical Sciences, Zhengzhou University, Zhengzhou, China. jtzhang@zzu.edu.cn.

Funding

Key Scientific and Technological Project of Henan Province 242102310387Project of Basic Research Fund of Henan Institute of Medical and Pharmacological Sciences 2024BP0102Project of Basic Research Fund of Henan Institute of Medical and Pharmacological Sciences 2024BP0203Project of Basic Research Fund of Henan Institute of Medical and Pharmacological Sciences 2024BP0206
6 · The paper itself

Abstract

backgroundAmorpha fruticosa was used for treating burn, ambustion, carbuncle, and eczema in the traditional Chinese medicine. Although more and more attention has been paid to its biological activity recently, the antitumor activities of the essential oils (EOs) extracted from its leaves (AFLEO) and flowers (AFFEO), and their molecular mechanisms have never been reported up to now. The objective of present study was to examine the chemical compositions of AFLEO and AFFEO, then investigate the effects and pharmacological mechanism of EOs against hepatocellular carcinoma (HCC).

methodsThe chemical compositions of EOs were examined using gas chromatography-mass spectrometry (GC-MS). The inhibitory effect of the EOs on HCC was evaluated by MTT assay. The detected components of AFLEO and AFFEO were performed ADME screening to examine their drug-likeness. Then a PPI network, compound-target network, compound-target-pathway network, gene ontology, and KEGG enrichment for HCC were applied to identify the targets and pathways for AFLEO and AFFEO against HCC. Molecular docking of the main components and their targets was performed to predict the binding affinity. Western blotting was used to verify the results.

results30 components were identified from AFLEO, while 22 components from AFFEO. Both AFLEO and AFFEO inhibited the proliferation of HCC cells in a time and dose-dependent manner. 10 compounds of AFLEO and 9 compounds of AFFEO were screened out for further analysis. 28 hub targets of AFLEO and 40 hub targets of AFFEO were detected by PPI network. KEGG analysis revealed that pathways in cancer, chemical carcinogenesis - receptor activation and proteoglycans in cancer were related to the EOs against HCC. Molecular docking confirmed that the main component of the EOs has high affinity to the targets of HCC.

conclusionsAFLEO and AFFEO may suppress HCC by acting on multiple targets and regulating multiple pathways.

Indexed as

Antineoplastic Agents, PhytogenicCarcinoma, HepatocellularLiver NeoplasmsOils, VolatileCell Line, TumorFlowersGas Chromatography-Mass SpectrometryHumansMolecular Docking SimulationNetwork PharmacologyPlant LeavesAntineoplastic Agents, PhytogenicOils, VolatileAmorpha fruticosaEssential oilGC-MSHCCMolecular dockingNetwork pharmacology

Identifiers

PMID39871242
PMCPMC11771004

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.